Newland Pharmaceutical Co., Ltd. (SHE:301277)

China · Delayed Price · Currency is CNY

11.94

-0.42 (-3.40%)

At close: Apr 9, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Pharmaceutical Intermediates			643.85M	621.21M	508.93M	433.12M	406.52M
Pharmaceutical Intermediates Growth			3.64%	22.06%	17.50%	6.54%	37.76%
Unallocated Other			7.59M	6.15M	4.91M	-	-
Unallocated Other Growth			23.34%	25.30%	-	-	-
Total			651.44M	627.36M	513.84M	433.12M	406.52M
Total Growth			3.84%	22.09%	18.64%	6.54%	37.76%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
China			641.16M	611.27M	500.11M	408.40M	386.95M
China Growth			4.89%	22.23%	22.45%	5.54%	44.21%
Foreign			10.28M	16.10M	13.73M	24.72M	19.57M
Foreign Growth			-36.15%	17.28%	-44.47%	26.31%	-26.91%
Total			651.44M	627.36M	513.84M	433.12M	406.52M
Total Growth			3.84%	22.09%	18.64%	6.54%	37.76%

Source: S&P Global Market Intelligence.